Promyelocytic Leukemia Protein (PML) Requirement for Interferon-induced Global Cellular SUMOylation

Mol Cell Proteomics. 2018 Jun;17(6):1196-1208. doi: 10.1074/mcp.RA117.000447. Epub 2018 Mar 13.

Abstract

We report that interferon (IFN) α treatment at short and long periods increases the global cellular SUMOylation and requires the presence of the SUMO E3 ligase promyelocytic leukemia protein (PML), the organizer of PML nuclear bodies (NBs). Several PML isoforms (PMLI-PMLVII) derived from a single PML gene by alternative splicing, share the same N-terminal region but differ in their C-terminal sequences. Introducing each of the human PML isoform in PML-negative cells revealed that enhanced SUMOylation in response to IFN is orchestrated by PMLIII and PMLIV. Large-scale proteomics experiments enabled the identification of 558 SUMO sites on 389 proteins, of which 172 sites showed differential regulation upon IFNα stimulation, including K49 from UBC9, the sole SUMO E2 protein. Furthermore, IFNα induces PML-dependent UBC9 transfer to the nuclear matrix where it colocalizes with PML within the NBs and enhances cellular SUMOylation levels. Our results demonstrate that SUMOylated UBC9 and PML are key players for IFN-increased cellular SUMOylation.

Keywords: Cytokines*; Interferon; Mass Spectrometry; PML; Post-translational modifications*; SUMO; Systems biology*; Tandem Mass Spectrometry; UBC9; Ubiquitinases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • HEK293 Cells
  • Humans
  • Interferon-alpha / pharmacology*
  • Promyelocytic Leukemia Protein / metabolism*
  • Sumoylation / drug effects*

Substances

  • Interferon-alpha
  • Promyelocytic Leukemia Protein